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Abstract: Hyperglycemia is a common occurrence in hospitalized patients receiving parenteral and/or
enteral nutrition. Although there are several approaches to manage hyperglycemia, there is no
consensus on the best practice. We systematically searched PubMed, Embase, Cochrane Central,
and ClinicalTrials.gov to identify records (published or registered between April 1999 and April
2019) investigating strategies to manage glucose control in adults receiving parenteral and/or enteral
nutrition whilst hospitalized in noncritical care units. A total of 15 completed studies comprising
1170 patients were identified, of which 11 were clinical trials and four observational studies. Diabetes
management strategies entailed adaptations of nutritional regimens in four studies, while the
remainder assessed different insulin regimens and administration routes. Diabetes-specific nutritional
regimens that reduced glycemic excursions, as well as algorithm-driven insulin delivery approaches
that allowed for flexible glucose-responsive insulin dosing, were both effective in improving glycemic
control. However, the assessed studies were, in general, of limited quality, and we see a clear need
for future rigorous studies to establish standards of care for patients with hyperglycemia receiving
nutrition support.
Keywords: glucose control; hyperglycemia; parenteral nutrition; enteral nutrition; nutritional
support; insulin
1. Introduction
Hyperglycemia is frequently encountered during parenteral (PN) and/or enteral (EN) nutrition in
hospitalized patients with and without pre-existing diabetes [1,2]. Indeed, it is estimated that more than
50% of patients on PN and 30% of patients on EN experience hyperglycemia whilst in the hospital [3,4].
Hyperglycemia arises in these patients due to one or more of the following factors: (1) diminished insulin
sensitivity due to inflammation, stress hormones, and sedentarism [5]; (2) increased carbohydrate
provision [6]; and (3) side-effects of medication such as glucocorticoids that interfere with glucose
metabolism [7]. In patients totally reliant on PN, these factors are compounded by the loss of the
physiological incretin effect on insulin release, as occurs when entirely bypassing the gastrointestinal
tract with intravenous nutrient supply [8]. Furthermore, the diminished glucose-stimulated insulin
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secretion in diabetic patients with some residual beta-cell function increases their requirement for
exogenous insulin.
Evidence from several observational studies suggests that emergent hyperglycemia during
nutrition support is associated with increased morbidity and mortality [1,9]. There is an apparently
linear relationship between the incidence of adverse outcomes and mean glucose levels once glycaemia
surpasses a threshold of 6.3 mM [10]. In individuals on PN, the risk of any complication increases by a
factor of 1.58 for each 1 mM increase in glycaemia above this threshold [11]. Conversely, treatment of
hyperglycemia is shown to improve clinical outcomes [12–15]. However, striving for tight glucose
control inherently increases the risk of hypoglycemia, which is similarly associated with adverse
clinical outcomes [16,17].
PN and EN nutrition support are provided in a number of ways, ranging from continuous to cyclic
regimens, often in combination with unpredictable and variable oral intake or additional intravenous
glucose administration. Maintaining glycemic control is even more demanding in patients with
unanticipated interruptions of their feeding (e.g., due to emergency surgery), or if nutrition support
is suspended due to accidental removal or obstruction of tubing. Guidelines such as those from the
American Diabetes Society [18] and the Endocrine Society [19] recommend that random blood glucose
levels be maintained below 10.0 mM, provided that this target can be safely achieved. According to
these guidelines, the mainstay of hyperglycemia management in the hospital is the administration of
insulin, given its high efficacy, flexibility, and lack of interference with most other pharmacotherapies
or organ dysfunctions.
Although there are some recommendations for insulin dosing tailored to the needs of patients
receiving PN and/or EN, there is a lack of evidence-based support for specific insulin regimens. Insulin
can be delivered via intravenous or subcutaneous routes, or in patients receiving PN, insulin may
simply be mixed in the nutrition solution [20]. Intravenous insulin infusion at a rate continuously
adjusted according to regular capillary blood glucose measurements helps to maintain glucose
levels within the recommended limits. However, implementation of intravenous protocols imposes
considerable demand on nursing staff, calling for two hours of direct nursing daily per patient [21],
which substantially increases the workload of ward staff. Noncritical care nurses have to manage
several patients, and staff levels are reduced at nighttime, which does not encourage constant vigilance
of blood glucose and manual adjustment of insulin infusion rates. Thus, for practical and safety
considerations in noncritical care settings, subcutaneous administration is the favored route for
insulin delivery. However, the formulation of PN and EN support can also influence glucose levels
in patients on nutrition support. Whereas glucose is the only carbohydrate source in standard PN
solutions, the glycemic impact can be modulated by changing the caloric contributions of carbohydrates
versus monounsaturated fatty acids (MUFAs), or by using alternate carbohydrates such as fructose.
Furthermore, the addition of fibers to EN formulae can delay carbohydrate absorption, thereby
attenuating the glycemic impact [22,23]. An overview of the different management strategies is
provided in Figure 1.
Diabetes technology has progressed greatly over the past decade, bringing considerable
improvements to the care of outpatients with type 1 and type 2 diabetes. Notably, recent development
of continuous glucose monitoring (CGM) systems that measure interstitial fluid glucose concentration
every few minutes allow to depict glucose profiles in higher resolution, thereby facilitating adjustment
of insulin dosages [24]. CGM systems also project trends for glucose levels and feature customizable
hypo- and hyperglycemia alerts. There is a growing interest in the use of this technology in hospital
settings given the abundance of additional information that can guide therapy adjustments.
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Figure 1. Management options of hyperglycemia during PN/EN. PN = parenteral nutrition, EN = 
enteral nutrition. 
An important variable in the control of glycaemia is the modulation of insulin to meet with the 
continuously changing metabolic needs. Due to its inherent flexibility of insulin dose adjustment, the 
predominant mode of delivery in patients with type 1 diabetes is via a subcutaneous insulin pump, 
also known as continuous subcutaneous insulin infusion [25]. Here, a portable pump infuses rapid-
acting insulin at a rate that can be altered on demand or preset to change at fixed times. This flexible 
adaptation of the insulin delivery profile makes the approach particularly attractive for patients 
under cyclic nutrition regimens who may receive large amounts of carbohydrates within predefined 
time windows. The combination of real-time glucose measurements from a CGM device with a 
control algorithm that directs insulin delivery via an insulin pump constitutes a closed-loop system, 
also known as the artificial pancreas [26,27]. Closed-loop systems automatically adjust insulin 
delivery every 10–12 min according to real-time glucose measurements. The autonomy and glucose 
feedback-regulation obtained through closed-loop systems hold promise in the particular context of 
hyperglycemia, arising along with nutritional support, while sparing an excess burden on nursing 
staff. 
Our aim in the present review is to provide an overview of the current status and future outlook 
of glucose management strategies for noncritical care patients receiving PN and/or EN nutrition 
support. 
2. Materials and Methods 
2.1. Literature Search 
This review was conducted and reported in accordance with the PRISMA and MOOSE 
guidelines [28,29]. Completed checklists can be found in Supplementary Tables S5 and S6. PubMed 
and Embase databases were used to identify relevant records over the past 20 years. The Cochrane 
Central Register of Controlled Trials and ClinicalTrials.gov were searched for published and ongoing 
studies. The search strategies for the databases are summarized in Supplementary Tables S1–S4. Two 
reviewers independently evaluated the titles and abstracts according to the selection criteria. For each 
potentially eligible study, two reviewers assessed the full-text. In cases of disagreement, a decision 
was made by consensus or, if necessary, a third reviewer was consulted. 
. t
n i portant variable in the control of glycae ia is the odulation of insulin to eet ith the
continuously changing metabolic needs. Due to its inherent flexibility of insulin dose adjustment,
the predominant mode of delivery in patients with type 1 diabetes is via a subcutaneous insulin
pump, also known as continuous subcutaneous insulin infusion [25]. Here, a portable pump infuses
rapid-acting insulin at a rate that can be altered on demand or preset to change at fixed times.
This flexible adaptation of the insulin delivery profile makes the approach particularly attractive for
patients under cyclic nutrition regimens who may receive large amounts of carbohydrates within
predefined time windows. The combination of real-time glucose easurements from a CGM device
with a control algorithm that directs insulin delivery via an insulin pump constitutes a closed-loop
system, also known as the artificial pancreas [26,27]. Closed-loop systems automatically adjust insulin
delivery every 10–12 in according to real-ti e glucose easure ents. The autono y and glucose
feedback-regulation obtained through closed-loop syste s hold pro ise in the particular context of
hyperglyce ia, arising along with nutritional support, while sparing an excess burden on nursing staff.
Our aim in the present review is to provide an overview of the current status and future outlook of
glucose management strategies for noncritical care patients receiving PN and/or EN nutrition support.
2. Materials and Methods
2.1. Literature Search
This review was conducted and reported in accordance with the PRISMA and MOOSE
guidelines [28,29]. Completed checklists can be found in Supplementary Tables S5 and S6. PubMed and
Embase databases were used to identify relevant records over the past 20 years. The Cochrane Central
Register of Controlled Trials and ClinicalTrials.gov were searched for published and ongoing studies.
The search strategies for the databases are summarized in Supplementary Tables S1–S4. Two reviewers
independently evaluated the titles and abstracts according to the selection criteria. For each potentially
eligible study, two reviewers assessed the full-text. In cases of disagreement, a decision was made by
consensus or, if necessary, a third reviewer was consulted.
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2.2. Study Selection Criteria
Studies were included if they met the following criteria: (i) were published or registered in
English language between 10 April 1999 and 10 April 2019 (date last searched); (ii) were clinical
studies evaluating new treatment approaches against a comparator; (iii) included adult (age ≥ 18 years)
noncritical care inpatients receiving PN and/or EN nutrition; (iv) investigated strategies to manage
blood glucose control; and (v) had outcomes reflecting glucose control. Exclusion criteria were
pregnancy, breast feeding, case reports, abstracts, guidelines, or literature reviews. The selection
process is shown in Figure 2.
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Two reviewers extracted data independently using a predesigned form, including study design, 
sample size, glucose management strategy, primary outcome, and main results. If no primary 
outcome was specified, we obtained the endpoints deemed most relevant. 
2.4. Quality Assessment 
The quality of clinical trials was evaluated by two reviewers based on the “Cochrane Risk of Bias 
tool” [30]. According to this tool, studies are judged to be of low or high risk for bias based on criteria 
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Figure 2. Flowchart illustrating the study selection process.
2.3. Data Extraction
Two reviewers extracted data independently using a predesigned form, including study design,
sample size, glucose management strategy, primary outcome, and main results. If no primary outcome
was specified, we obtain d the endpoints deemed most r levant.
2.4. Quality Assessment
The quality of clinical trials was evaluated by two reviewers based on the “Cochrane Risk of Bias
tool” [30]. According to this tool, studi s are judged to be of low or h gh risk for bias ba ed on criteria
to evaluate random sequence generation, allocation concealment, blindin of participants/personnel
and outcome assessment, incomplete outcome data, and selective reporting. Since retrospective
publications have an inherently high risk of bias in most domains, and there is not a standardized
assessment tool available, we refrained them from quality evaluation.
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3. Results
3.1. Study Identification and Selection
We identified in total 745 potentially eligible records. Following screening based on titles
and abstracts, 34 citations were selected for detailed full-text evaluation. Of those, 16 articles met
the selection criteria and were included in the review (Figure 2). One ongoing study was eligible
for inclusion.
3.2. Characteristics of the Included Studies
The included published publications comprised 1170 participants from 15 clinical studies, of which
11 were clinical trials (9 randomized and 2 nonrandomized) and 4 were retrospective observational
studies. One study was an ongoing registered study. Seven studies were conducted in Europe, three in
North America, and five in Asia. Only three studies included more than one center. The study
population represented medical (20%), surgical (27%), or mixed medical and surgical (53%) noncritical
care inpatients. Three studies explicitly stated the inclusion of patients with type 1 diabetes, three studies
explicitly excluded patients with type 1 diabetes, five studies exclusively recruited patients with type 2
diabetes, whereas the remainder did not further characterize the diabetic state of study participants or
the reason for hyperglycemia (n = 4). Nutrition support comprised PN in six studies, EN in seven
studies, and PN and/or EN in two studies. Regarding glucose management strategies, 4 studies
investigated nutritional approaches, and 11 studies explored insulin interventions. No studies were
found that explored noninsulin pharmacological strategies. The study duration ranged from 36 h to
46 days. Study characteristics and findings are summarized in Tables 1 and 2.
Four of the clinical trials were considered of medium quality, indicating a low risk of bias in
all domains except for performance and detection bias, which was deemed reasonable with a near
impossibility of blinding [31–34]. The other studies were deemed to be of limited quality, with high
risk of bias in the domains of lack of primary outcome definition and selective or incomplete reporting
(Supplementary Figure S1). Since retrospective publications have an inherently high risk of bias in
most domains, we refrained from a quality evaluation of the four such studies.
3.3. Studies Examining Nutritional Strategies
Four studies examined nutritional strategies to manage glycaemia in patients receiving nutrition
support. The use of EN formulae with lower glycemic impacts were contrasted against conventional
products in two clinical trials [35,36]. In a nonrandomized crossover study involving inpatients
with type 2 diabetes, Tiyapanjanit et al. tested a formula compounded in-house to contain 50% of
calories as carbohydrates, thereof 67% as fructose, in comparison with an iso-energetic control formula
(53% of calories as carbohydrates and 15% as fructose). Over the study period of 36 h, lower mean
glucose was achieved with the high-fructose formula compared to control (6.8 ± 1.5 vs. 8.0 ± 2.1 mM,
p = 0.022). No insulin or antidiabetic medication was administered in these patients [35]. Similarly,
a four-center randomized controlled parallel trial conducted in 104 inpatients with type 2 diabetes
found a lower nutrition-induced relative change from baseline glycaemia with the use of lower glycemic
impact enteral vs. standard enteral nutrition formula (10% vs. 21%, p = 0.006). The investigated EN
formula contained a reduced amount of carbohydrates (9.4 vs. 12.5 g/100 mL, p = n/a) and higher
amounts of MUFAs (3.8 vs. 1.0 g/100 mL, p = n/a) [36]. Similarly, an ongoing randomized clinical trial
(GlyENStroke, NCT03422900) evaluates the efficacy of a diabetes-specific enteral nutrition formula
to reduce hyperglycemia (glucose levels > 8.3 mM) in nondiabetic patients with hyperglycemia on
nutrition support after stroke [37].
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Table 1. Overview of clinical trials.
Author, Year Study Design 1 Sample Size Population
Nutrition
Therapy Interventions
Primary Outcome
{Study Period} Main Results Risk of Bias
3
Insulin adaptation
Boughton et al., 2019 [31] RCT, parallel,
two-center
43
Non-T1D
surgical and
medical
PN and/or EN
Fully automated s.c.
closed-loop insulin
delivery (closed loop,
n = 21)
% time in target (5.6–10.0 mM)
based on CGM values
{Up to 15 d or discharge}
% time in target higher in closed-loop vs. control (68%
vs. 36%, p < 0.0001); hypoglycemia (<3.9 mM)
infrequent and similar between closed-loop and
control (0.5% for both), p = ns)
Low
Conventional s.c. insulin
therapy according to local
practice (control, n = 22)
Olveira et al., 2019 [32]
RCT, parallel,
multi-center
(26 sites)
161
T2D
surgical and
medical
TPN
100% regular insulin in
PN bag (100% in bag,
n = 80) Mean glucose based on capillary
POC BG values
{Up to 15 d or until PN stop}
Mean glucose during TPN 9.2 vs. 9.6 mM 100% in
bag vs. 50% in bag (ns); mean glucose 48 h post-TPN
higher in 100% in bag vs. 50% in bag (8.9 vs. 7.9 mM,
p = 0.024); number of patients with hypoglycemia
(≤3.9 mM) lower in 100% in bag vs. 50% in bag
(9 vs. 22, p = 0.016)
Medium
50% s.c. glargine + 50%
regular insulin in PN bag
(50% in bag, n = 81)
Li et al., 2018 [38]
RCT, parallel,
single-center 102
T2D
surgical
PN (cyclic)
Continuous s.c. insulin
infusion (CSII, n = 50) mean amplitude of glycemic
excursion (MAGE) based on CGM
{4 d}
MAGE lower in CSII vs. basbol (3.7 vs. 6.2 mM,
p < 0.05), no hypoglycemia events (<3.9 mM)
occurred
HighS.c. basal–bolus
glargine/aspart (basbol,
n = 52)
Hakeam et al., 2017 [33]
RCT, parallel,
single-center 67
Non-T1D
surgical
(non-cardiac)
PN
S.c. glargine (scGlarg,
n = 35)
Mean glucose based on capillary
POC BG values from day 5 on PN
and % of patients who achieved
target glycaemia (7.8–10.0 mM)
{9 d}
Comparable mean BG in scGlar vs. RIbag, % of
values in target 52% in scGlar vs. 48% in RIbag
(p = 0.06); no significant difference in hypoglycemic
(<3.9 mM) events
Medium
Regular insulin added to
PN bag (RIbag, n = 32)
Yuan et al., 2015 [12]
RCT, parallel,
single-center 212
T2D
surgical
(gastrectomy for
gastric cancer)
EN (continuous)
VRII (short-acting insulin
NOS) (VRII, n = 106)
PO not specified; mean glucose
based on capillary POC BG values,
infective and noninfective
complications
{8–10 d}
Mean BG lower in VRII vs. s.c.Ins. (5.4 vs. 9.5 mM, p
< 0.001); higher rate of severe hypoglycemia (≤2.2
mM) in VRII vs. s.c.Ins. (8% vs. 1%, p = 0.035)
High
S.c. conventional insulin
therapy (s.c.Ins., n = 106)
Kruyt et al., 2010 [39]
Single-arm
intervention
with historical
control
23
Hyperglycemic
patients
(excluded
patients with
previous insulin
use)medical
(stroke unit)
EN
Continuous feeding with
computerized VRII group
(continuous, n = 10)
% of capillary POC BG values in
target range (4.4–6.1 mM){5 d}
Higher % values in target and mean glucose in
continuous vs. inter group (55% vs. 19%, p < 0.005
and 5.8 vs. 7.6 mM, p < 0.005)
Medium
Bolus feeding with
regular i.v. insulin
adaptation intermediate
group (inter, n = 13)
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Table 1. Cont.
Author, Year Study Design 1 Sample Size Population
Nutrition
Therapy Interventions
Primary Outcome
{Study Period} Main Results Risk of Bias
3
Korytkowski et al.,
2009 [40]
RCT, parallel,
single-center 50
Diabetes NOS
surgical and
medical
EN
S.c. SSI (regular insulin)
every 4–6 h (SSRI, n = 25);
(NPH initialized if
persistent BG > 10.0 mM)
PO not specified; mean glucose
based on capillary POC BG values
{8 d}
mean BG similar in SSRI and basalPLUS (8.9 vs.
9.2 mM, p = ns); NPH initialized in 55% of those on
SSRI
High
S.c. SSRI plus s.c.
glargine (basalPLUS,
n = 25)
Nutrition adaptation
Tiyapanjanit et al.,
2014 [35]
Non-randomized
cross-over (no
washout)
10
T2D (BG < 10
mM wo
antidiabetic
medication)
medical
EN (continuous)
In-house prepared EN
formula with 50% CHO
thereof 67% fructose,
(inhouse, n = 10) PO not specified; mean glucose
based on capillary POC BG values;
glycemic variability based on CGM
{3 d, each formula for 36 h)
Mean glucose lower in inhouse vs. standard group
(6.8 vs. 8.0 mM, p = 0.022); glucose variability
comparable
HighStandard diabetic EN
formula with 53% CHO
thereof 15% fructose and
57% maltodextrin
(standard, n = 10)
Lidder et al., 2009 [34]
RCT, parallel,
single-center
30
Prediabetes
(fasting BG < 7
mM)
surgical
(esophagectomy
for esophageal
cancer)
PN with or wo
EN
100% of energy covered
by PN (PN, n = 14)
Mean glucose values based on
CGM values
{surgery until postoperative day 5}
Mean glucose comparable over entire study period,
lower from day 3 post-surgery to day 5 post-surgery
in PN + EN vs. PN (p = 0.002)
Medium70% covered by PN +
30% covered by EN (PN +
EN, n = 16)
Léon-Sanz et al., 2005 [36]
RCT, parallel,
multi-center
(4 sites)
104 T2D surgical
and medical
EN (continuous)
Low-CHO high-MUFA
nutrition formula
(lowCHO, n = 51) Mean glucose based on capillary
POC BG values and mean daily
insulin dose
{2 weeks}
BG increase from baseline lower in lowCHO than
highCHO after 7 d on EN (10% vs. 21%, p = 0.006);
mean BG identical (12.7 vs. 12.7 mM2)
MediumEnergy-matched
high-CHO nutrition
formula (highCHO,
n = 53)
Valero et al., 2001 [41]
RCT, parallel,
double-blind,
single-center
138
T1D (21%) and
T2D (79%)
surgical and
medical
TPN
(continuous)
Standard TPN containing
glucose (PN_G, n = 71) PO not specified; number of
patients with target glycaemia
(capillary POC BG values 8.3–11.1
mM) at end of TPN
{TPN duration 5–46 d)
BG < 11.1 mM at end of TPN reached in 75% vs. 85%
in PN_G and PN_GFX respectively 2
HighEnergy-matched TPN
containing
glucose:fructose:xylitol
2:1:1 (PN_GFX, n = 67)
RCT = randomized controlled trial, T1D = type 1 diabetes, EN = enteral nutrition, PN = parenteral nutrition, s.c. = subcutaneous, CGM = continuous glucose monitoring, T2D = type
2 diabetes, TPN = total parenteral nutrition, POC = point of care, BG = blood glucose, (ns) = not significant, CSII = continuous subcutaneous insulin infusion, VRII = variable rate
intravenous insulin, excl = exclusion, NOS = not otherwise specified, PO = primary outcome, SSI = sliding scale insulin, SSRI = sliding-scale regular insulin, NPH = neutral protamine
Hagedorn insulin, wo = without, i.v. = intravenous, CHO = carbohydrates, h = hours, d = day(s) and MUFA = monounsaturated fatty acids. 1 Open-label if not stated otherwise. 2 No
p-value available. 3 Overall quality assessment; specific domains can be found in Supplementary Figure S1.
J. Clin. Med. 2019, 8, 935 8 of 17
Table 2. Overview of observational, retrospective studies.
Author, Year Study Design Sample Size Population NutritionTherapy Interventions
Primary Outcome
{Study Period} Main Results
Insulin adaptation
Truong et al.,
2019 [42]
Retrospective
observational,
single-center
102
Hyperglycemic patients
(≥ 2 BG values > 10.0
mM, including T1D and
T2D)
surgical and medical
PN (continuous or
cyclic)
Regular insulin added to
PN bag (100% bag, n = 78) % of patients with ≥5/6 capillary POC
BG values per day <10.0 mM for
≥2 consecutive days
{during PN or until target reached}
Higher % of patients with target achieved in 100%bag
vs. scGlarg (72% vs. 49%, p = 0.017);
≥2 hypoglycemic events (<3.9 mM) in 9% of 100%bag
and 17% of scGlarg group (p = ns); lower need for
corrective insulin less in 100%bag vs. scGlarg (28 vs.
57% of patients, p = 0.003)
S.c. insulin glargine
(scGlarg, n = 35)
Hijaze et al.,
2017 [43]
Retrospective
observational,
single-center
53 Non-T1D
medical
EN (continuous)
S.c. NPH insulin 3×/day
(NPH, n = 26)
(Rescue bolus with 6 units
rapid insulin analoga if
BG > 16.7 mM)
PO not specified; mean glucose based
on capillary POC BG values and % of
values in the target range (7.8–10 mM)
{until discharge or stop EN}
mean BG comparable in NPH vs. basbol (10.6 vs. 11.1
mM, p = ns), 24% and 22% of values in range (p = ns)
S.c. basal–bolus insulin
analoga therapy (basbol,
n = 27)
Neff et al.,
2014 [44]
Retrospective
observational,
single-center
53
Hyperglycemic patients
(BG > 10 mM including
T1D and T2D)
surgical and medical
PN
Protocol-driven VRII
(VRII, n = 32)
PO not specified; mean glucose based
on POC BG values and % of values in
target range (4.0–10.0 mM)
{until stop PN}
Mean glucose lower and % values in target range higher
in VRII vs. basbol (9.6 vs. 11.2 mM, p = 0.009 and 62%
vs. 43%, p = 0.008)
S.c. basal–bolus insulin
(basbol, n = 21)
Hsia et al.,
2011 [45]
Retrospective
observational,
single-center
22
Diabetes NOS
surgical and medical EN (continuous)
S.c. basal–bolus with
glargine/lispro (basbol, n
= 8)
PO not specified; mean glucose based
on POC BG values, % of values in
target range (7.8–10.0 mM)
{72 h}
mean glucose comparable, % of values in target range
higher in mixed3 vs. mixed2 and basbol (69% vs. 22%
vs. 24%, p < 0.01); patients with hypoglycemic events
(<3.9 mM) in basbol vs. mixed2 and mixed3
(5 vs. 2 vs. 1)
S.c. 70/30 premixed
insulin 2×/day (mixed2, n
= 8)
S.c. 70/30 pre-mixed
insulin 3×/day (mixed3, n
= 6)
BG = blood glucose, vs. = versus, T1D = type 1 diabetes, T2D = type 2 diabetes, PN = parenteral nutrition, s.c. = subcutaneous, POC = point of care, EN = enteral nutrition, NPH = Neutral
Protamine Hagedorn, ns = not significant, VRII = variable rate intravenous insulin, PO = primary outcome, and NOS = not otherwise specified.
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There was only one study examining a modified nutritional formula in abdominal surgery patients
that were entirely parenterally fed. In this randomized parallel double-blind single-center study,
Valero et al. contrasted a PN formula with glucose as a sole carbohydrate source with an iso-energetic
PN formulation containing a 2:1:1 glucose:fructose:xylitol carbohydrate mixture. The study population
consisted of patients with type 1 diabetes (21%) or type 2 diabetes (79%). Both formulae provided a
similar total amount of carbohydrates (2.9 ± 0.5 vs. 2.9 ± 0.7 g/kg/day), but the test formula under
investigation contained less glucose (2.9 ± 0.5 vs. 1.5 ± 0.4 g/kg/day). Protein and fat quantity were
similar. The time until attaining target glycaemia (8.3–11.1 mM) did not significantly differ (2.5 ± 1.7
vs. 2.4 ± 2.1 day, p = ns), nor did the percentage of patients attaining values below 11.1 mM (75% vs.
85%, p = ns) and total daily insulin dose (45 ± 19 vs. 45 ± 26 U/day, p = ns). However, when stratified
according to the occurrence of sepsis, the nonseptic patients showed lower insulin requirements with
the glucose–fructose–xylitol regime (37 ± 17 vs. 44 ± 17 U/day, p = 0.026) [41].
Managing glycaemia during PN is more demanding than during EN. In this context,
the combination of PN with EN, in addition to its well-established trophic benefits on gastrointestinal
function, may also confer glycemic advantages. This was shown by a randomized controlled parallel
study performed by Lidder et al. in patients undergoing esophagectomy who received nutrition
support for up to five days post-surgery. The study contrasted the coverage of 30% of energy needs by
EN and 70% by PN feeds with 100% coverage by PN. Although no effect was seen in mean glucose
over the five-day study period, the combined use of EN and PN lead to lower glycaemia three days
after surgery (p = 0.002) [34].
3.4. Studies Examining Insulin Strategies
Eleven studies examined insulin-based strategies to manage glucose in patients receiving nutrition
support (five with PN, five with EN, and one with combined PN/EN). A randomized controlled
single-center parallel study involving 212 type 2 diabetic patients who had undergone gastrectomy for
gastric cancer compared protocol-driven intravenous insulin therapy with conventional subcutaneous
sliding scale insulin delivery over 8–10 days of continuous EN. Mean glucose levels were lower (5.4 ± 1.2 vs.
9.5 ± 1.8 mM, p < 0.001), and mean daily insulin doses were higher (55 ± 15 vs. 32 ± 16 U/day, p < 0.001)
in patients receiving intravenous insulin compared with subcutaneous insulin. However, in the
group receiving intravenous insulin, eight participants experienced episodes of severe hypoglycemia
(defined as blood glucose < 2.2 mM), versus only one participant in the subcutaneous group (p = 0.010).
Additionally, this study reported outcomes extending beyond glycemic control, finding a reduced
incidence of surgical site infection in the intravenous insulin group [12].
A second randomized controlled trial (RCT) evaluating different insulin treatments during EN
included 50 patients with non-type 1 diabetes who were randomly assigned to receive sliding scale
subcutaneous regular insulin either with or without once daily subcutaneous glargine. In the group
without glargine administration, subcutaneous neutral protamine Hagedorn (NPH, isophane) was
given as a rescue medication when glucose levels exceeded 10.0 mM. Mean glucose as the primary
outcome was comparable between groups, as were the number of hypoglycemic events and total daily
insulin dose. However, NPH was required in 48% of the control participants, as their glucose levels
were not sufficiently controlled with the regular sliding scale subcutaneous insulin alone [40].
A single-arm trial evaluated the efficacy of a computerized variable rate insulin infusion rate
protocol in previously insulin-naïve stroke patients on continuous EN over five days. Compared to a
historical control population who received enteral bolus feeds accompanied by intravenous insulin
coverage, the intervention resulted in a higher percentage of values in the target range of 4.4–6.1 mM
(55% vs. 19%, p < 0.005) [39].
Additionally, two retrospective observational studies evaluated insulin-based strategies to treat
hyperglycemia in hospitalized patients receiving EN. Hijaze et al. found comparable mean glucose
values, and similar times with glucose values within the target range (7.8–10 mM), in patients receiving
subcutaneous NPH insulin thrice daily vs. basal–bolus insulin therapy with insulin analogues [43].
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In the second such study, Hsia et al. retrospectively evaluated glucose control using three different
insulin regimens in patients with diabetes of type not otherwise specified during at least three days
of continuous EN. Treatment consisted of (1) 70/30 biphasic insulin (NPH/regular) every 8 h (n = 6),
(2) 70/30 biphasic insulin every 12 h (n = 8), and (3) a basal–bolus regimen (glargine and lispro, n = 8).
The 8 h 70/30 biphasic insulin group had the highest proportion of glucose values falling within the
target range (7.8–10.0 mM) (69% vs. 22% vs. 24%, p < 0.01). Hypoglycemic events (<3.9 mM) occurred
five times in glargine/lispro group, twice in the twice-daily biphasic group, and once in the thrice-daily
biphasic group [45]. In patients receiving PN, two randomized controlled parallel trials evaluated
strategies that involved the addition of regular insulin to the PN feeding bag. Olveira et al. recently
compared the use of 100% coverage of insulin needs by regular insulin added to the PN bag with 50%
coverage by regular insulin added to the PN bag and 50% administered subcutaneously as insulin
glargine in a total of 161 mixed surgical and medical patients with type 2 diabetes recruited at 26
different sites. The glucose values of participants were evaluated while receiving total PN (maximum
of 15 days) and two days after cessation of total PN. Mean glucose levels during total PN did not
significantly differ between groups (9.2 ± 2.0 vs. 9.6 ± 2.4 mM, p = ns); however, mean glucose two days
after cessation of total PN was higher in the group that had received 100% of their exogenous insulin
requirements added to the PN feeding bag (8.9 ± 2.5 vs. 7.9 ± 2.4 mM, p = 0.024). The authors did not
provide any details on the requirement for insulin therapy after cessation of nutrition support [32].
Another randomized controlled clinical trial of PN patients contrasted two different basal insulin
regimens. Hakeam et al. compared subcutaneous basal–bolus therapy (insulin glargine + short-acting
insulin analogue) with the addition of regular insulin to the PN bag in a total of 67 non-type 1 diabetic
patients. Both groups received additional corrective regular subcutaneous insulin according to a
sliding scale. Basal insulin delivery dose was titrated based on glucose values by a daily 40%–60%
dose increase if glucose values were still above target. The percentage of glucose values within the
glycemic target range (7.8–10.0 mM) tended to be higher in the group who received s.c. insulin glargine
compared to those who received regular insulin added to the PN bag (52% vs. 48%, p = 0.06). Mean
glucose levels and number of hypoglycemic events did not differ between treatment groups [33].
In contrast to these prospective findings in PN patients, a retrospective evaluation performed by
Truong et al. in 102 patients on PN showed superior glucose control defined as percentage of patients
with ≥5 of 6 glucose values <10 mM over 2 days in those who had received 100% of required insulin
added to the PN bag (n = 78), compared with those treated with subcutaneous insulin glargine (n = 35)
(72% vs. 49%, p = 0.017). Additionally, fewer patients receiving insulin via the PN bag experienced
two or more hypoglycemic events compared to those with subcutaneous administration (9% vs. 17.1%,
p = ns) [42].
As reviewed above in patients receiving EN, a protocol-driven intravenous insulin delivery
approach has proven to confer glycemic benefits in PN patients, according to a retrospective analysis
performed by Neff et al. A total of 53 surgical and medical patients requiring insulin therapy whilst
in the hospital were treated either with protocol-driven variable rate intravenous insulin (n = 32),
or received basal–bolus subcutaneous insulin therapy (n = 21). The insulin infusion group compared
to the group receiving subcutaneous basal–bolus insulin therapy showed lower mean glucose levels
(9.6 ± 2.1 vs. 11.2 ± 2.6 mM, p = 0.009) and a higher percentage of glucose values within the glycemic
target of 4.0–10.0 mM (62% vs. 43%, p = 0.008), without increased risk of hypoglycemia [44].
Two recently performed randomized controlled parallel design trials evaluated insulin pump
therapy, also known as continuous subcutaneous insulin infusion (CSII), in patients receiving nutrition
support. The study performed by Li et al. compared the use of CSII (n = 50) to basal–bolus therapy using
insulin glargine in combination with insulin aspart (n = 52) in patients receiving PN. Study treatment
was initialized before surgery, and PN began on day 1 after surgery, with comparison of glucose control
with CGM from postoperative day 1 to day 5. Glycemic variability was assessed by mean amplitude of
glucose excursion (MAGE) as the primary outcome. CSII reduced glycemic variability compared to
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basal–bolus injection therapy (3.7 ± 2.8 vs. 6.2 ± 3.0 mM, p < 0.05). No hypoglycemic events occurred
in either treatment group [38].
The second study evaluated CSII as part of a fully automated subcutaneous closed-loop glucose
control (n = 21) against conventional subcutaneous insulin therapy according to local practice (n = 22)
in two different hospitals. Randomization was stratified according to BMI, prestudy total daily insulin
dose, and type of nutrition support to ensure to demographic balance between groups. The closed-loop
system consisted of a subcutaneous insulin pump, a CGM device, and a control algorithm, which
adjusted insulin delivery every 12 min based on real-time CGM values. An example of such fully
automated closed-loop insulin delivery is illustrated in Figure 3. Participants were recruited from
medical and surgical wards and received PN (n = 13), EN (n = 27), or combined PN/EN (n = 3).
The primary outcome was the proportion of time when sensor glucose was within the target range
(5.6–10.0 mM). Participants were followed for up to 15 days or until hospital discharge. The closed-loop
system nearly doubled the proportion of time spent in the glycemic target range compared to control
(68% ± 16% vs. 36% ± 27%, p < 0.0001). Time spent above target, mean glucose level, and glucose
variability were all significantly lower in the closed-loop group. Hypoglycemia was infrequent in both
arms, and its incidence did not differ significantly. The substantially better glycemic control in the
closed-loop compared to the control group was achieved with a similar total daily insulin dose (53.9 vs.
40.3 U, p = ns) [31].
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absorption in EN formulae have proven effective in various studies as well as in meta-analyses [22,23].
The use of diabetes-specific enteral formulae is therefore supported by the expert group of the European
Society of Clinical Nutrition and Metabolism (ESPEN) for patients with a history of diabetes [46].
With respect to PN formulae, glucose substitutes such as fructose or xylitol to lower the glycemic
impact are no longer used in clinical practice. This may relate to previously reported metabolic side
effects of parenteral xylitol and fructose such as formation of oxalate crystals in the kidney and lactate
accumulation [47–49]. To ake matters worse, life-threatening metabolic complications can occur in
patients with undeclared hereditary fructose intolerance [50]. There is currently no data on the efficacy
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and safety of PN formulations with reduced carbohydrate content (and consequently higher protein
or lipid fractions) in noncritically ill patients with hyperglycemia. In critically ill patients, however,
lipid-based, compared to iso-energetic glucose-based, PN formulae showed more favorable metabolic
effects [51]. Additionally, lowering the overall carbohydrate and energy provision has proven effective
in reducing hyperglycemia in critically ill patients [52,53].
As an alternative to conventional routes of insulin administration, algorithm-driven intravenous
insulin titration protocols during both PN and EN achieved superior glucose control compared
to subcutaneous approaches with either sliding scale or basal–bolus insulin therapy. However,
this approach poses logistical challenges for ward staff, given the need for frequent glucose draws and
insulin dose adjustments, which are either impractical or simply unfeasible in noncritical care settings
with low nurse-to-patient ratios. Regarding subcutaneous insulin regimens, administering basal plus
supplemental short-acting insulin analogues showed superior efficacy compared to a sliding scale
approach with short-acting insulin. The administration of intermediate or long-acting insulins can thus
be recommended for PN/EN patients receiving subcutaneous insulin therapy. No data exist with regard
to the use of recently introduced ultra-long acting insulins (e.g., degludec). Of note, the required time to
reach steady state insulin levels with ultra-long acting formulations imposes certain constraints on the
titration method, and prediposes to dysglycemia. There is a practical consideration that administering
long-acting insulin in previously insulin-naïve patients brings a risk of hypoglycemia if feeding tubes
are accidentally pulled or obstructed.
The admixture of insulin into the PN feeding bag is a safe and effective alternative to using short-
or rapid-acting subcutaneous insulin. Moreover, further advantages lie in the lesser need for nursing
time, the concomitant discontinuation of insulin delivery upon PN interruption, and the consequently
lower risk of hypoglycemic events. The latter is particularly relevant for patients in whom the transient
need for exogenous insulin is primarily a result of their nutrition support. However, the need for strict
aseptic conditions may render the procedure impractical or not permissible. Furthermore, reservations
exist regarding the diminished or highly variable efficacy of PN insulin due to interference from PN
ingredients or bag surface material [54,55].
Irrespective to the chosen approach for insulin administration, a limiting factor in obtaining tight
glucose control is the risk of inadvertent hypoglycemia [17]. As is the case for hyperglycemia, iatrogenic
hypoglycemia is associated with increased cost and adverse medical outcomes [16]. In this context,
there is an increasing interest in the use of noninsulin glucose-lowering agents (without hypoglycemia
risk) for the treatment of inpatient hyperglycemia. The recent SITA-HOSPITAL randomized controlled
study investigated 279 noncritical care patients with type 2 diabetes and showed that oral sitagliptin
plus basal insulin led to similar glycemic control than the more labor-intensive basal–bolus insulin
regimen [56]. However, challenging patients such as those with high insulin requirements, renal
failure, or use of glucocorticoids were excluded from the study. Currently, there are no data on
the inpatient use of noninsulin glucose-lowering treatments for hyperglycemia in noncritical care
patients on PN and/or EN. Reservations apply to the common side effects of noninsulin treatments
(e.g., incretin-based therapies) on the gastrointestinal tract, which is often the primary pathophysiology
calling for nutrition support. Further research is needed to explore the potential risks and benefits of
noninsulin pharmacotherapy for managing glucose levels in noncritical care settings with EN/PN.
The high prevalence of hyperglycemia amongst noncritical care patients on PN and/or EN support,
in conjunction with the increasing workload burden placed on hospital staff, brings an urgent need
for innovative approaches to improve the efficacy, efficiency, and safety of healthcare delivery in
this context. The advent of novel technologies such as automated closed-loop systems that titrate
insulin delivery based on real-time sensor glucose measurements could potentially address this need,
whilst reducing staff workload burden. Uncertainties remain with respect to interference with certain
medications and inaccurate glucose readouts related to compromised microcirculation. In addition,
we concede that there are short-term costs to purchase, install, and train staff in the use of any novel
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technology. Ongoing studies will further document the potential role of this technology and the
obstacles to its integration into clinical practice without disrupting the usual workflow.
The present systematic review turned up rather few randomized controlled trials and a limited
number of retrospective observational studies addressing hyperglycemia in noncritical care patients
on PN and/or EN. The studies were highly heterogeneous in terms of study population, nutrition
regimen, study endpoints, and glucose measurement techniques. Patients with pre-existing diabetes
already on insulin treatment before their admission to the hospital and those receiving steroids or
showing impaired renal function clearly have different optimal insulin delivery profiles compared
to patients without pre-existing diabetes and/or with stress-induced hyperglycemia. The particular
nutrition regime (i.e., the EN/PN feeding schedule and any additional oral intake) leads to variable
carbohydrate exposures with relevant impact on insulin requirements. The few studies that utilized
CGM more comprehensively assessed both hyper- and hypoglycemic excursions, whilst studies
adopting intermittent (i.e., six-hourly) point-of-care measurements may have missed important events
such as postprandial transients. Most studies were conducted in patients on continuous PN and/or
EN, which may be less demanding for insulin management compared to the less common bolus or
cyclic feeding practices. The scarce evidence and the many factors (e.g., patient comorbidity, staffing
level, hospital guidelines, and policies) that determine the ability and capacity to treat hyperglycemia
effectively and safely challenge the provision of generalizable treatment recommendations. In Figure 4,
we propose a workflow recommendation considering both nutritional and insulin adaptation to
manage hyperglycemia in the noncritical care population receiving nutrition support.
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The majority of the included studies scored poorly in methodology, with a high or unclear risk of
biases according to Cochrane criteria. Undoubtably, it is sometimes difficult or unethical to undertake
double-blind RCTs with standardized protocols. Also, some studies did not correct for multiple testing,
which may have overestimated outcomes. The included retrospective observational studies were not
evaluated for quality given the known risk of outcome overestimation and confounding biases inherent
in that design. However, we chose to report these studies in this review to cover the widest possible
range of different management possibilities.
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Small sample sizes and short study durations of some studies may have led to an underestimation
of effect sizes, thus hindering the sensitivity to ascertain the efficacy of potential methods to improve
glycemic control or indeed to confirm the impact of superior glucose control on patient outcomes.
There is clearly a need for further research in the form of well-designed and adequately powered
multicenter trials of sufficient duration aiming to examine effects of glucose management strategies on
glucose control, clinical outcome, and also optimization of nutritional status in patients receiving PN
and/or EN.
5. Conclusions
The management of hyperglycemia in patients receiving PN and/or EN presents unique clinical
challenges for both diabetic and nondiabetic hospitalized patients with hyperglycemia. Coherent
approaches to this problem are important to avoid potential complications. Obtaining a better match
between the carbohydrate dose and the insulin supply is likely to improve glucose control. Granting
more attention to the glycemic impact of nutrition regimes in conjunction with deploying novel
technologies such as CGM and glucose-responsive automation of insulin delivery through closed-loop
systems may address these needs without increasing staff workload. Supplemental or alternate use of
noninsulin pharmacological approaches may further open up new lines of research. Well-designed
and adequately powered randomized controlled trials are necessary to define the optimal management
of hyperglycemia and consequent clinical benefits in patients receiving nutrition support.
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